Impact of latency time on survival for adolescents and young adults with a second primary malignancy

Melanie Goldfarb, Aaron Rosenberg, Qian Li, Theresa H Keegan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND: The adverse impact of second primary malignancies (SPMs) on survival is substantial for adolescents and young adults (AYAs; ie, those 15-39 years old). No studies have evaluated whether the latency time between the first malignancy (the primary malignancy [PM]) and the SPM affects cancer-specific survival (CSS). METHODS: A multivariate Cox proportional hazards regression with Surveillance, Epidemiology, and End Results data for 13 regions from 1992 to 2008 was used to ascertain whether the latency time (1-5 vs≥6 years) to the development of an SPM affected the CSS and overall survival with respect to either the PM or SPM for AYAs with common SPMs. RESULTS: The majority of 1515 AYAs with an SPM had their PM diagnosed between the ages of 26 and 39 years (74.2%) and an SPM diagnosed within 1 to 5 years (72.9%) of the PM's diagnosis. Overall, AYAs that developed an SPM 1 to 5 years after the diagnosis (vs≥6 years) had an increased risk of death from cancer (hazard ratio [HR], 2.52; 95% confidence interval [CI], 1.92-3.29) as well as any cause (HR, 2.60; 95% CI, 2.04-3.32). Specifically, for AYAs with an SPM that was leukemia or a colorectal, breast, or central nervous system malignancy, a shorter latency time (1-5 years) from their PM diagnosis was associated with an overall significantly increased risk of death (2.6-fold) from either their PM or that particular SPM. However, latency did not appear to affect the CSS with respect to either the PM or SPM for AYA patients with a lymphoma or sarcoma SPM. CONCLUSIONS: Most AYAs who develop an SPM do so within 1 to 5 years of their primary cancer diagnosis, and they have an increased risk of death from cancer in comparison with AYAs with an SPM developing after longer survivorship intervals.

Original languageEnglish (US)
JournalCancer
DOIs
StateAccepted/In press - Jan 1 2017

Fingerprint

Second Primary Neoplasms
Young Adult
Neoplasms
Survival
Confidence Intervals
Sarcoma
Lymphoma

Keywords

  • Adolescent
  • Adolescents and young adults (AYAs)
  • Latency
  • Second cancer
  • Young adult

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Impact of latency time on survival for adolescents and young adults with a second primary malignancy. / Goldfarb, Melanie; Rosenberg, Aaron; Li, Qian; Keegan, Theresa H.

In: Cancer, 01.01.2017.

Research output: Contribution to journalArticle

@article{a5b68b0c13a1447e8dfc4483301cf0dd,
title = "Impact of latency time on survival for adolescents and young adults with a second primary malignancy",
abstract = "BACKGROUND: The adverse impact of second primary malignancies (SPMs) on survival is substantial for adolescents and young adults (AYAs; ie, those 15-39 years old). No studies have evaluated whether the latency time between the first malignancy (the primary malignancy [PM]) and the SPM affects cancer-specific survival (CSS). METHODS: A multivariate Cox proportional hazards regression with Surveillance, Epidemiology, and End Results data for 13 regions from 1992 to 2008 was used to ascertain whether the latency time (1-5 vs≥6 years) to the development of an SPM affected the CSS and overall survival with respect to either the PM or SPM for AYAs with common SPMs. RESULTS: The majority of 1515 AYAs with an SPM had their PM diagnosed between the ages of 26 and 39 years (74.2{\%}) and an SPM diagnosed within 1 to 5 years (72.9{\%}) of the PM's diagnosis. Overall, AYAs that developed an SPM 1 to 5 years after the diagnosis (vs≥6 years) had an increased risk of death from cancer (hazard ratio [HR], 2.52; 95{\%} confidence interval [CI], 1.92-3.29) as well as any cause (HR, 2.60; 95{\%} CI, 2.04-3.32). Specifically, for AYAs with an SPM that was leukemia or a colorectal, breast, or central nervous system malignancy, a shorter latency time (1-5 years) from their PM diagnosis was associated with an overall significantly increased risk of death (2.6-fold) from either their PM or that particular SPM. However, latency did not appear to affect the CSS with respect to either the PM or SPM for AYA patients with a lymphoma or sarcoma SPM. CONCLUSIONS: Most AYAs who develop an SPM do so within 1 to 5 years of their primary cancer diagnosis, and they have an increased risk of death from cancer in comparison with AYAs with an SPM developing after longer survivorship intervals.",
keywords = "Adolescent, Adolescents and young adults (AYAs), Latency, Second cancer, Young adult",
author = "Melanie Goldfarb and Aaron Rosenberg and Qian Li and Keegan, {Theresa H}",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/cncr.31170",
language = "English (US)",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Impact of latency time on survival for adolescents and young adults with a second primary malignancy

AU - Goldfarb, Melanie

AU - Rosenberg, Aaron

AU - Li, Qian

AU - Keegan, Theresa H

PY - 2017/1/1

Y1 - 2017/1/1

N2 - BACKGROUND: The adverse impact of second primary malignancies (SPMs) on survival is substantial for adolescents and young adults (AYAs; ie, those 15-39 years old). No studies have evaluated whether the latency time between the first malignancy (the primary malignancy [PM]) and the SPM affects cancer-specific survival (CSS). METHODS: A multivariate Cox proportional hazards regression with Surveillance, Epidemiology, and End Results data for 13 regions from 1992 to 2008 was used to ascertain whether the latency time (1-5 vs≥6 years) to the development of an SPM affected the CSS and overall survival with respect to either the PM or SPM for AYAs with common SPMs. RESULTS: The majority of 1515 AYAs with an SPM had their PM diagnosed between the ages of 26 and 39 years (74.2%) and an SPM diagnosed within 1 to 5 years (72.9%) of the PM's diagnosis. Overall, AYAs that developed an SPM 1 to 5 years after the diagnosis (vs≥6 years) had an increased risk of death from cancer (hazard ratio [HR], 2.52; 95% confidence interval [CI], 1.92-3.29) as well as any cause (HR, 2.60; 95% CI, 2.04-3.32). Specifically, for AYAs with an SPM that was leukemia or a colorectal, breast, or central nervous system malignancy, a shorter latency time (1-5 years) from their PM diagnosis was associated with an overall significantly increased risk of death (2.6-fold) from either their PM or that particular SPM. However, latency did not appear to affect the CSS with respect to either the PM or SPM for AYA patients with a lymphoma or sarcoma SPM. CONCLUSIONS: Most AYAs who develop an SPM do so within 1 to 5 years of their primary cancer diagnosis, and they have an increased risk of death from cancer in comparison with AYAs with an SPM developing after longer survivorship intervals.

AB - BACKGROUND: The adverse impact of second primary malignancies (SPMs) on survival is substantial for adolescents and young adults (AYAs; ie, those 15-39 years old). No studies have evaluated whether the latency time between the first malignancy (the primary malignancy [PM]) and the SPM affects cancer-specific survival (CSS). METHODS: A multivariate Cox proportional hazards regression with Surveillance, Epidemiology, and End Results data for 13 regions from 1992 to 2008 was used to ascertain whether the latency time (1-5 vs≥6 years) to the development of an SPM affected the CSS and overall survival with respect to either the PM or SPM for AYAs with common SPMs. RESULTS: The majority of 1515 AYAs with an SPM had their PM diagnosed between the ages of 26 and 39 years (74.2%) and an SPM diagnosed within 1 to 5 years (72.9%) of the PM's diagnosis. Overall, AYAs that developed an SPM 1 to 5 years after the diagnosis (vs≥6 years) had an increased risk of death from cancer (hazard ratio [HR], 2.52; 95% confidence interval [CI], 1.92-3.29) as well as any cause (HR, 2.60; 95% CI, 2.04-3.32). Specifically, for AYAs with an SPM that was leukemia or a colorectal, breast, or central nervous system malignancy, a shorter latency time (1-5 years) from their PM diagnosis was associated with an overall significantly increased risk of death (2.6-fold) from either their PM or that particular SPM. However, latency did not appear to affect the CSS with respect to either the PM or SPM for AYA patients with a lymphoma or sarcoma SPM. CONCLUSIONS: Most AYAs who develop an SPM do so within 1 to 5 years of their primary cancer diagnosis, and they have an increased risk of death from cancer in comparison with AYAs with an SPM developing after longer survivorship intervals.

KW - Adolescent

KW - Adolescents and young adults (AYAs)

KW - Latency

KW - Second cancer

KW - Young adult

UR - http://www.scopus.com/inward/record.url?scp=85038236240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038236240&partnerID=8YFLogxK

U2 - 10.1002/cncr.31170

DO - 10.1002/cncr.31170

M3 - Article

C2 - 29205296

AN - SCOPUS:85038236240

JO - Cancer

JF - Cancer

SN - 0008-543X

ER -